Dr. Ramez N. Eskander, M.D
Gynecologic Oncology (Gynecologic Oncology Physician)
1200 Garden View Rd
Encinitas, CA 92024
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Diego School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 126
Licensed in California since 2008, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of California, San Diego School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
CA license A102482 (first issued 2008; current) -
Obstetrics & Gynecology Physician
CA license A102482 (first issued 2008; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UC San Diego Health Hillcrest - Hillcrest Med Ctr San Diego, CA
Medical groups
- Regents of the University of California (2,089 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 126
- Services billed
- 503
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 211 | 69 |
| Established patient office or other outpatient visit, 30-39 minutes | 153 | 80 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 38 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
| Established patient office or other outpatient visit, 20-29 minutes | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Encinitas, CA | 41 |
| Prochlorperazine Maleate Other prescribers in Encinitas, CA | 34 |
| Lynparza (olaparib) | 27 |
| Ondansetron Hcl Other prescribers in Encinitas, CA | 26 |
| Levothyroxine Sodium Other prescribers in Encinitas, CA | 14 |
| Megestrol Acetate Other prescribers in Encinitas, CA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 92 payments worth $169,928 in total to this clinician.
| Merck Sharp & Dohme LLC | $88,745 |
|---|---|
| GlaxoSmithKline, LLC. | $17,267 |
| Eisai Inc. | $11,003 |
| Regeneron Pharmaceuticals, Inc. | $9,641 |
| Genmab U.S., Inc. | $6,179 |
| AbbVie Inc. | $5,847 |
| Daiichi Sankyo Inc. | $5,251 |
| Beone Medicines USA, Inc. | $5,200 |
| Consulting Fee | $75,306 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $51,586 |
| Travel and Lodging | $39,362 |
| Education | $2,139 |
| Food and Beverage | $1,535 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jul 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,880 |
| Merck Sharp & Dohme LLC Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,370 |
| Merck Sharp & Dohme LLC Sep 18, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Prague, Czech Republic · in-kind | $9,973 |
| Merck Sharp & Dohme LLC Mar 29, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $8,870 |
| Merck Sharp & Dohme LLC Sep 10, 2025 | Travel and Lodging travel to Sao Paulo, Brazil · in-kind | $7,800 |
| Merck Sharp & Dohme LLC Sep 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Merck Sharp & Dohme LLC Jul 18, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $7,418 |
| GlaxoSmithKline, LLC. Apr 23, 2025 | Consulting Fee | $7,200 |
All 62 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Dec 23, 2025 | Consulting Fee | $1,454 |
| Merck Sharp & Dohme LLC Dec 10, 2025 | Consulting Fee | $2,880 |
| Beone Medicines USA, Inc. Dec 2, 2025 | Consulting Fee | $1,625 |
| Gilead Sciences, Inc. Nov 21, 2025 | Consulting FeeCompany’s description;4212673;GTF;10395730 | $2,710 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Travel and Lodging travel to Cape Town, South Africa | $150 |
| Merck Sharp & Dohme LLC Nov 7, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Cape Town, South Africa · in-kind | $123 |
| Merck Sharp & Dohme LLC Nov 4, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Cape Town, South Africa · in-kind | $123 |
| AstraZeneca UK Limited Oct 31, 2025 | Consulting Fee ENHERTU · Oncology | $410 |
| Genmab U.S., Inc. Oct 24, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $2,000 |
| AstraZeneca Pharmaceuticals LP Oct 24, 2025 | Consulting Fee LYNPARZA · Oncology | $1,370 |
| Merck Sharp & Dohme LLC Oct 6, 2025 | Compensation for services other than consulting (speaking, faculty) | $896 |
| Merck Sharp & Dohme LLC Sep 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Merck Sharp & Dohme LLC Sep 29, 2025 | Travel and Lodging travel to Prague, Czech Republic | $150 |
| Merck Sharp & Dohme LLC Sep 20, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Prague, Czech Republic · in-kind | $60.43 |
| Merck Sharp & Dohme LLC Sep 19, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Prague, Czech Republic · in-kind | $162 |
| Merck Sharp & Dohme LLC Sep 18, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Prague, Czech Republic · in-kind | $9,973 |
| Merck Sharp & Dohme LLC Sep 18, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Prague, Czech Republic · in-kind | $162 |
| Merck Sharp & Dohme LLC Sep 18, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Prague, Czech Republic · in-kind | $53.28 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Beone Medicines USA, Inc. Sep 12, 2025 | Consulting Fee | $650 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging travel to Sao Paulo, Brazil · in-kind | $579 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging travel to Sao Paulo, Brazil · in-kind | $116 |
| Merck Sharp & Dohme LLC Sep 10, 2025 | Travel and Lodging travel to Sao Paulo, Brazil · in-kind | $7,800 |
| Genmab U.S., Inc. Aug 1, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $800 |
| Merck Sharp & Dohme LLC Jul 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,880 |
| Merck Sharp & Dohme LLC Jul 30, 2025 | Travel and Lodging travel to Tokyo, Japan | $150 |
| Genmab U.S., Inc. Jul 25, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $3,200 |
| Merck Sharp & Dohme LLC Jul 18, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $7,418 |
| Merck Sharp & Dohme LLC Jul 18, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $208 |
| GlaxoSmithKline, LLC. Jul 10, 2025 | Consulting Fee | $6,400 |
| Beone Medicines USA, Inc. Jul 9, 2025 | Consulting Fee | $1,950 |
| AstraZeneca Pharmaceuticals LP Jun 2, 2025 | Consulting Fee | $1,370 |
| Eli Lilly and Company Jun 1, 2025 | Education in-kind | $2,139 |
| Corcept Therapeutics May 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,200 |
| Beone Medicines USA, Inc. May 16, 2025 | Consulting Fee | $975 |
| Regeneron Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee | $3,600 |
| Regeneron Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee | $1,800 |
| GlaxoSmithKline, LLC. May 2, 2025 | Consulting Fee | $1,200 |
| GlaxoSmithKline, LLC. Apr 23, 2025 | Consulting Fee | $7,200 |
| Eisai Inc. Apr 23, 2025 | Consulting Fee | $2,445 |
| Merck Sharp & Dohme LLC Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,370 |
| Merck Sharp & Dohme LLC Apr 7, 2025 | Travel and Lodging travel to Tokyo, Japan | $150 |
| Eisai Inc. Apr 2, 2025 | Consulting Fee Lenvima · Oncology | $3,668 |
| Merck Sharp & Dohme LLC Mar 29, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $8,870 |
| Merck Sharp & Dohme LLC Mar 29, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $636 |
| Merck Sharp & Dohme LLC Mar 29, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $159 |
| Daiichi Sankyo Inc. Mar 19, 2025 | Consulting Fee | $1,860 |
| Daiichi Sankyo Inc. Mar 12, 2025 | Consulting Fee | $1,860 |
| Incyte Corporation Mar 11, 2025 | Consulting Fee | $3,105 |
| AstraZeneca UK Limited Mar 7, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,100 |
| Merck Sharp & Dohme LLC Mar 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,200 |
| Merck Sharp & Dohme LLC Mar 3, 2025 | Travel and Lodging travel to Rome, Italy | $150 |
| AstraZeneca Pharmaceuticals LP Feb 24, 2025 | Consulting Fee | $685 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee | $3,150 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee | $900 |
| AbbVie Inc. Feb 19, 2025 | Consulting Fee | $5,800 |
| Eisai Inc. Feb 5, 2025 | Consulting Fee Lenvima · Oncology | $4,890 |
| GlaxoSmithKline, LLC. Feb 5, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $1,810 |
| GlaxoSmithKline, LLC. Feb 5, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $193 |
| GlaxoSmithKline, LLC. Feb 5, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $169 |
| Eli Lilly and Company Jan 24, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $448,069 in research payments for these studies, mostly to the institutions running them.
- A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company · Recruiting · NCT06400472 - A phase iii randomized, placebo-controlled study of pembrolizumab MK-3475, nsc #776864 in addition to paclitaxel and carboplatin for measurable stage iii or iva, stage ivb or recurrent endometrial cancer
Merck Sharp & Dohme LLC - A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Genmab U.S., Inc. - Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie Inc. · Active, not recruiting · NCT05445778 - A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient dMMR Advanced or Recurrent Endometrial Ca…
Merck Sharp & Dohme LLC - First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie Inc. · Active, not recruiting · NCT05527184
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.